Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006769 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL8840602 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL69669 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL23221351 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL18900975 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL23561000 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL13007137 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL23352964 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL4088388 | 0.97 | ALDH1A1 (0.53) | ALDH1A1THRBMEN1KMT2A | |
| SCHEMBL22348939 | 0.94 | ALDH1A1 (0.50) | ALDH1A1THRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 217/4885THRB 1668/4885MEN1 3602/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALDH1A1 242/4885THRB 1610/4885MEN1 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.